Skip to content
2000
Volume 3, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

A metabolic illness that affects around 25% of the world's population, metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with numerous more ailments. It is associated with dementia progression, influenced by factors like brain insulin resistance, cerebrovascular dysfunction, gut dysbiosis, and neuroinflammation. Furthermore, other MASLD characteristics like systemic inflammation, vascular dysfunction, and sleep apnea are also strongly linked to cognitive dysfunction. Recent research suggests MASLD could contribute to cognitive impairment even without these factors. As dementia and MASLD share clinical characteristics and underlying metabolic risk factors, further research is needed to find effective treatments for both. This study discusses the shared pathogenic traits and mechanisms of dementia and MASLD. Additionally, this review discusses various non-medication and medication treatment strategies along with the different types of nano formulation studies for the treatment of MASLD

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906321699241004070130
2024-11-06
2025-10-25

  • From This Site

    /content/journals/ijghd/10.2174/0126662906321699241004070130
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. YounossiZ.M. KoenigA.B. AbdelatifD. FazelY. HenryL. WymerM. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes.Hepatology2016641738410.1002/hep.2843126707365
     [Google Scholar]
  2. WongR.J. AguilarM. CheungR. PerumpailR.B. HarrisonS.A. YounossiZ.M. AhmedA. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.Gastroenterology2015148354755510.1053/j.gastro.2014.11.03925461851
     [Google Scholar]
  3. DysonJ. JaquesB. ChattopadyhayD. LochanR. GrahamJ. DasD. AslamT. PatanwalaI. GaggarS. ColeM. SumpterK. StewartS. RoseJ. HudsonM. ManasD. ReevesH.L. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team.J. Hepatol.201460111011710.1016/j.jhep.2013.08.01123978719
     [Google Scholar]
  4. WongV.W-S. WongG.L-H. ChoiP.C-L. ChanA.W-H. LiM.K-P. ChanH-Y. Disease progression of MASLDisease: A prospective study with paired liver biopsies at 3 years.Gut201059796910.1136/gut.2009.20508820581244
     [Google Scholar]
  5. AnguloP. KleinerD. E. Dam-LarsenS. AdamsL. A. BjornssonE. S. CharatcharoenwitthayaP. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver diseaseGastroenterology20151492389397
     [Google Scholar]
  6. LombardiR. FargionS. FracanzaniA.L. Brain involvement in MASLDisease (MASLD): A systematic review.Dig. Liver Dis.20195191214122210.1016/j.dld.2019.05.01531176631
     [Google Scholar]
  7. NicholsE. SzoekeC.E.I. VollsetS.E. AbbasiN. Abd-AllahF. AbdelaJ. AichourM.T.E. AkinyemiR.O. AlahdabF. AsgedomS.W. AwasthiA. Barker-ColloS.L. BauneB.T. BéjotY. BelachewA.B. BennettD.A. BiadgoB. BijaniA. Bin SayeedM.S. BrayneC. CarpenterD.O. CarvalhoF. Catalá-LópezF. CerinE. ChoiJ-Y.J. DangA.K. DegefaM.G. DjalaliniaS. DubeyM. DukenE.E. EdvardssonD. EndresM. EskandariehS. FaroA. FarzadfarF. FereshtehnejadS-M. FernandesE. FilipI. FischerF. GebreA.K. GeremewD. Ghasemi-KasmanM. GnedovskayaE.V. GuptaR. HachinskiV. HagosT.B. HamidiS. HankeyG.J. HaroJ.M. HayS.I. IrvaniS.S.N. JhaR.P. JonasJ.B. KalaniR. KarchA. KasaeianA. KhaderY.S. KhalilI.A. KhanE.A. KhannaT. KhojaT.A.M. KhubchandaniJ. KisaA. Kissimova-SkarbekK. KivimäkiM. KoyanagiA. KrohnK.J. LogroscinoG. LorkowskiS. MajdanM. MalekzadehR. MärzW. MassanoJ. MengistuG. MeretojaA. MohammadiM. Mohammadi-KhanaposhtaniM. MokdadA.H. MondelloS. MoradiG. NagelG. NaghaviM. NaikG. NguyenL.H. NguyenT.H. NirayoY.L. NixonM.R. Ofori-AsensoR. OgboF.A. OlagunjuA.T. OwolabiM.O. Panda-JonasS. PassosV.M.A. PereiraD.M. Pinilla-MonsalveG.D. PiradovM.A. PondC.D. PoustchiH. QorbaniM. RadfarA. ReinerR.C.Jr RobinsonS.R. RoshandelG. RostamiA. RussT.C. SachdevP.S. SafariH. SafiriS. SahathevanR. SalimiY. SatpathyM. SawhneyM. SaylanM. SepanlouS.G. ShafieesabetA. ShaikhM.A. SahraianM.A. ShigematsuM. ShiriR. ShiueI. SilvaJ.P. SmithM. SobhaniS. SteinD.J. Tabarés-SeisdedosR. Tovani-PaloneM.R. TranB.X. TranT.T. TsegayA.T. UllahI. VenketasubramanianN. VlassovV. WangY-P. WeissJ. WestermanR. WijeratneT. WyperG.M.A. YanoY. YimerE.M. YonemotoN. YousefifardM. ZaidiZ. ZareZ. VosT. FeiginV.L. MurrayC.J.L. GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol.20191818810610.1016/S1474‑4422(18)30403‑430497964
     [Google Scholar]
  8. FrisardiV. SolfrizziV. SeripaD. CapursoC. SantamatoA. SancarloD. VendemialeG. PilottoA. PanzaF. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer’s disease.Ageing Res. Rev.20109439941710.1016/j.arr.2010.04.00720444434
     [Google Scholar]
  9. NdumeleC. NasirK. ConceiçãoR.D. CarvalhoJ.A. BlumenthalR.S. SantosR.D. Hepatic Steatosis, Obesity and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation.Am Heart Assoc.2010
     [Google Scholar]
  10. BoursierJ. MuellerO. BarretM. MachadoM. FizanneL. Araujo-PerezF. GuyC.D. SeedP.C. RawlsJ.F. DavidL.A. HunaultG. ObertiF. CalèsP. DiehlA.M. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology201663376477510.1002/hep.2835626600078
     [Google Scholar]
  11. ElliottC. FrithJ. DayC.P. JonesD.E. NewtonJ.L. Functional impairment in alcoholic liver disease and MASLDisease is significant and persists over 3 years of follow-up.Dig. Dis. Sci.2013582383239110.1007/s10620‑013‑2657‑223609794
     [Google Scholar]
  12. CelikbilekA. CelikbilekM. BozkurtG. Cognitive assessment of patients with nonalcoholic fatty liver disease.Eur. J. Gastroenterol. Hepatol.201830894495010.1097/MEG.000000000000113129608442
     [Google Scholar]
  13. SaverJ.L. CushmanM. Striving for ideal cardiovascular and brain health: It is never too early or too late.JAMA2018320764564710.1001/jama.2018.1100230140858
     [Google Scholar]
  14. LeM.H. DevakiP. HaN.B. JunD.W. TeH.S. CheungR.C. Prevalence of MASLDisease and risk factors for advanced fibrosis and mortality in the United States.PLoS One2017123e017349910.1371/journal.pone.017349928346543
     [Google Scholar]
  15. CollieA. Cognition in liver disease.Liver Int.20052511810.1111/j.1478‑3231.2005.01012.x15698392
     [Google Scholar]
  16. LampignanoL. DonghiaR. GrisetaC. LagravineseG. SciarraS. ZupoR. CastellanaF. BortoneI. GuerraV. TirelliS. De NucciS. TatoliR. LozuponeM. SborgiaG. LeoA. De PergolaG. GiannelliG. PanzaF. SardoneR. Liver health and dementia in an Italian older population: Findings from the salus in apulia study.Front. Aging Neurosci.20211374888810.3389/fnagi.2021.74888834955810
     [Google Scholar]
  17. GeorgeE.S. SoodS. DalyR.M. TanS-Y. Is there an association between MASLDisease and cognitive function? A systematic review.BMC Geriatr.20222214710.1186/s12877‑021‑02721‑w35016619
     [Google Scholar]
  18. SeoS.W. GottesmanR.F. ClarkJ.M. HernaezR. ChangY. KimC. HaK.H. GuallarE. LazoM. Nonalcoholic fatty liver disease is associated with cognitive function in adults.Neurology201686121136114210.1212/WNL.000000000000249826911638
     [Google Scholar]
  19. TakahashiA. KonoS. WadaA. OshimaS. AbeK. ImaizumiH. Reduced brain activity in female patients with MASLDisease as measured by near-infrared spectroscopy.PLoS One2017124e017416910.1371/journal.pone.017416928376101
     [Google Scholar]
  20. ShangY. NasrP. EkstedtM. WidmanL. StålP. HultcrantzR. MASLDisease does not increase dementia risk although histology data might improve risk predictionJHEP reports202132
     [Google Scholar]
  21. GerberY. VanWagnerL.B. YaffeK. TerryJ.G. RanaJ.S. ReisJ.P. MASLDisease and cognitive function in middle-aged adults: The CARDIA study.BMC Gastroenterol.20212111910.1186/s12876‑021‑01681‑033407176
     [Google Scholar]
  22. SolfrizziV. ScafatoE. CustoderoC. LoparcoF. CiavarellaA. PanzaF. SeripaD. ImbimboB.P. LozuponeM. NapoliN. PiazzollaG. GalluzzoL. GandinC. BaldereschiM. Di CarloA. InzitariD. PilottoA. SabbàC. Italian Longitudinal Study on Aging Working Group Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging.Alzheimers Dement. 202061e1206510.1002/trc2.1206532864415
     [Google Scholar]
  23. TuttolomondoA. PettaS. CasuccioA. MaidaC. CorteV.D. DaidoneM. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with MASLDisease (MASLD): A case control study.Cardiovasc. Diabetol.201817111210.1186/s12933‑018‑0670‑729301528
     [Google Scholar]
  24. KjærgaardK. MikkelsenA.C.D. WernbergC.W. GrønkjærL.L. EriksenP.L. DamholdtM.F. Cognitive dysfunction in MASLDisease—current knowledge, mechanisms and perspectives.J. Clin. Med.202110467310.3390/jcm1004067333572481
     [Google Scholar]
  25. WeinsteinA.A. de AvilaL. PaikJ. GolabiP. EscheikC. GerberL. Cognitive performance in individuals with MASLDisease and/or type 2 diabetes mellitus.Psychosomatics201859656757410.1016/j.psym.2018.06.00130086995
     [Google Scholar]
  26. FilipovićB. MarkovićO. ĐurićV. FilipovićB. Cognitive changes and brain volume reduction in patients with nonalcoholic fatty liver disease.Can. J. Gastroenterol. Hepatol.201820181610.1155/2018/963879729682494
     [Google Scholar]
  27. WeinsteinG. Davis-PlourdeK. HimaliJ.J. Zelber-SagiS. BeiserA.S. SeshadriS. Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham Study.Liver Int.20193991713172110.1111/liv.1416131155826
     [Google Scholar]
  28. BajajJ.S. The role of microbiota in hepatic encephalopathy.Gut Microbes20145339740310.4161/gmic.2868424690956
     [Google Scholar]
  29. AhluwaliaV. BetrapallyN.S. HylemonP.B. WhiteM.B. GillevetP.M. UnserA.B. FaganA. DaitaK. HeumanD.M. ZhouH. SikaroodiM. BajajJ.S. Impaired gut-liver-brain axis in patients with cirrhosis.Sci. Rep.2016612680010.1038/srep2680027225869
     [Google Scholar]
  30. BajajJ.S. BetrapallyN.S. HylemonP.B. HeumanD.M. DaitaK. WhiteM.B. UnserA. ThackerL.R. SanyalA.J. KangD.J. SikaroodiM. GillevetP.M. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.Hepatology20156241260127110.1002/hep.2781925820757
     [Google Scholar]
  31. MieleL. ValenzaV. La TorreG. MontaltoM. CammarotaG. RicciR. MascianàR. ForgioneA. GabrieliM.L. PerottiG. VecchioF.M. RapacciniG. GasbarriniG. DayC.P. GriecoA. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.Hepatology20094961877188710.1002/hep.2284819291785
     [Google Scholar]
  32. IlanY. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis.World J. Gastroenterol.201218212609261810.3748/wjg.v18.i21.260922690069
     [Google Scholar]
  33. LiuR. KangJ.D. SartorR.B. SikaroodiM. FaganA. GavisE.A. ZhouH. HylemonP.B. HerzogJ.W. LiX. LippmanR.H. Gonzalez-MaesoJ. WadeJ.B. GhoshS. GurleyE. GillevetP.M. BajajJ.S. Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant.Hepatology202071261162610.1002/hep.3082731220352
     [Google Scholar]
  34. MohammedS.K. MagdyY.M. El-WaseefD.A.A. NabihE.S. HamoudaM.A. El-kharashiO.A. Modulation of hippocampal TLR4/BDNF signal pathway using probiotics is a step closer towards treating cognitive impairment in NASH model.Physiol. Behav.202021411276210.1016/j.physbeh.2019.11276231786271
     [Google Scholar]
  35. NgT.P. FengL. NyuntM.S.Z. FengL. GaoQ. LimM.L. CollinsonS.L. ChongM.S. LimW.S. LeeT.S. YapP. YapK.B. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia: Follow-up of the Singapore longitudinal ageing study cohort.JAMA Neurol.201673445646310.1001/jamaneurol.2015.489926926205
     [Google Scholar]
  36. VanhanenM. KoivistoK. MoilanenL. HelkalaE.L. HänninenT. SoininenH. KervinenK. KesäniemiY.A. LaaksoM. KuusistoJ. Association of metabolic syndrome with Alzheimer disease.Neurology200667584384710.1212/01.wnl.0000234037.91185.9916966548
     [Google Scholar]
  37. HanE. LeeJ.Y. HanK. ChoH. KimK.J. LeeB.W. KangE.S. ChaB.S. YounossiZ.M. LeeY. Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes.Sci. Rep.2020101680010.1038/s41598‑020‑63803‑032322005
     [Google Scholar]
  38. LabenzC. KostevK. KapsL. GalleP.R. SchattenbergJ.M. Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany.Dig. Dis. Sci.20216693179318510.1007/s10620‑020‑06644‑133037968
     [Google Scholar]
  39. SmithE.E. EgorovaS. BlackerD. KillianyR.J. MuzikanskyA. DickersonB.C. TanziR.E. AlbertM.S. GreenbergS.M. GuttmannC.R.G. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.Arch. Neurol.20086519410010.1001/archneurol.2007.2318195145
     [Google Scholar]
  40. ZeltserN. MeyerI. HernandezG.V. TrahanM.J. FanterR.K. Abo-IsmailM. GlanzH. StrandC.R. BurrinD.G. La FranoM.R. ManjarínR. MajM. Neurodegeneration in juvenile Iberian pigs with diet-induced nonalcoholic fatty liver disease.Am. J. Physiol. Endocrinol. Metab.20203193E592E60610.1152/ajpendo.00120.202032744096
     [Google Scholar]
  41. KimD-G. KrenzA. ToussaintL.E. MaurerK.J. RobinsonS-A. YanA. MASLDisease induces signs of Alzheimer’s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model.J. Neuroinflammation20161311810.1186/s12974‑015‑0467‑526728181
     [Google Scholar]
  42. LiM. LiX. LuY. Obstructive sleep apnea syndrome and metabolic diseases.Endocrinology201815972670267510.1210/en.2018‑0024829788220
     [Google Scholar]
  43. MussoG. CassaderM. OlivettiC. RosinaF. CarboneG. GambinoR. Association of obstructive sleep apnoea with the presence and severity of non‐alcoholic fatty liver disease. A systematic review and meta‐analysis.Obes. Rev.201314541743110.1111/obr.1202023387384
     [Google Scholar]
  44. SavranskyV. BevansS. NanayakkaraA. LiJ. SmithP.L. TorbensonM.S. PolotskyV.Y. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver.Am. J. Physiol. Gastrointest. Liver Physiol.20072934G871G87710.1152/ajpgi.00145.200717690174
     [Google Scholar]
  45. EriksenP.L. SoerensenM. GrønbækH. Hamilton-DutoitS. VilstrupH. ThomsenK.L. MASLDisease causes dissociated changes in metabolic liver functions.Clin. Res. Hepatol. Gastroenterol.201943555156010.1016/j.clinre.2019.01.00130770336
     [Google Scholar]
  46. BegricheK. MassartJ. RobinM.A. BonnetF. FromentyB. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease.Hepatology20135841497150710.1002/hep.2622623299992
     [Google Scholar]
  47. AldridgeD.R. TranahE.J. ShawcrossD.L. Pathogenesis of hepatic encephalopathy: Role of ammonia and systemic inflammation.J. Clin. Exp. Hepatol.20155Suppl. 1S7S2010.1016/j.jceh.2014.06.00426041962
     [Google Scholar]
  48. HäussingerD. KircheisG. FischerR. SchliessF. DahlS. Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema?J. Hepatol.20003261035103810.1016/S0168‑8278(00)80110‑510898326
     [Google Scholar]
  49. CagninA. KassiouM. MeikleS.R. BanatiR.B. Positron emission tomography imaging of neuroinflammation.Neurotherapeutics20074344345210.1016/j.nurt.2007.04.00617599710
     [Google Scholar]
  50. FelipoV. UriosA. MontesinosE. MolinaI. Garcia-TorresM.L. CiveraM. Del OlmoJ.A. OrtegaJ. Martinez-VallsJ. SerraM.A. CassinelloN. WasselA. JordáE. MontoliuC. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.Metab. Brain Dis.2012271515810.1007/s11011‑011‑9269‑322072427
     [Google Scholar]
  51. HigarzaS.G. ArboleyaS. GueimondeM. Gómez-LázaroE. AriasJ.L. AriasN. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits.PLoS One2019149e022301910.1371/journal.pone.022301931539420
     [Google Scholar]
  52. HaukelandJ.W. DamåsJ.K. KonopskiZ. LøbergE.M. HaalandT. GoverudI. TorjesenP.A. BirkelandK. BjøroK. AukrustP. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.J. Hepatol.20064461167117410.1016/j.jhep.2006.02.01116618517
     [Google Scholar]
  53. Tosello-TrampontA.C. LandesS.G. NguyenV. NovobrantsevaT.I. HahnY.S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.J. Biol. Chem.201228748401614017210.1074/jbc.M112.41701423066023
     [Google Scholar]
  54. DixonL.J. FlaskC.A. PapouchadoB.G. FeldsteinA.E. NagyL.E. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis.PLoS One201382e5610010.1371/journal.pone.005610023409132
     [Google Scholar]
  55. ViscogliosiG. AndreozziP. ChiriacI.M. CiprianiE. ServelloA. MariglianoB. EttorreE. MariglianoV. Depressive symptoms in older people with metabolic syndrome: Is there a relationship with inflammation?Int. J. Geriatr. Psychiatry201328324224710.1002/gps.381722639424
     [Google Scholar]
  56. ObermeierB. DanemanR. RansohoffR.M. Development, maintenance and disruption of the blood-brain barrier.Nat. Med.201319121584159610.1038/nm.340724309662
     [Google Scholar]
  57. MilanskiM. DegasperiG. CoopeA. MorariJ. DenisR. CintraD.E. TsukumoD.M.L. AnheG. AmaralM.E. TakahashiH.K. CuriR. OliveiraH.C. CarvalheiraJ.B.C. BordinS. SaadM.J. VellosoL.A. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: Implications for the pathogenesis of obesity.J. Neurosci.200929235937010.1523/JNEUROSCI.2760‑08.200919144836
     [Google Scholar]
  58. YangQ. ZhouJ. Neuroinflammation in the central nervous system: Symphony of glial cells.Glia20196761017103510.1002/glia.2357130548343
     [Google Scholar]
  59. BalzanoT. FortezaJ. BorredaI. MolinaP. GinerJ. LeoneP. UriosA. MontoliuC. FelipoV. Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis.J. Neuropathol. Exp. Neurol.201877983784510.1093/jnen/nly06130016459
     [Google Scholar]
  60. RongL. ZouJ. RanW. QiX. ChenY. CuiH. Advancements in the treatment of MASLDisease (MASLD).Front. Endocrinol.202313
     [Google Scholar]
  61. AkutaN. KawamuraY. FujiyamaS. SaitoS. MuraishiN. SezakiH. HosakaT. KobayashiM. KobayashiM. AraseY. IkedaK. SuzukiF. SuzukiY. KumadaH. Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study.Hepatol. Commun.2022692286229710.1002/hep4.200535581956
     [Google Scholar]
  62. KahlS. OfstadA.P. ZinmanB. WannerC. SchülerE. SattarN. InzucchiS.E. RodenM. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.Diabetes Obes. Metab.20222461061107110.1111/dom.1467035166009
     [Google Scholar]
  63. ItoD. ShimizuS. InoueK. SaitoD. YanagisawaM. InukaiK. AkiyamaY. MorimotoY. NodaM. ShimadaA. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.Diabetes Care201740101364137210.2337/dc17‑051828751548
     [Google Scholar]
  64. TobitaH. YazakiT. KataokaM. KotaniS. OkaA. MishiroT. OshimaN. KawashimaK. IshimuraN. NaoraK. SatoS. IshiharaS. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study.J. Clin. Biochem. Nutr.202168217318010.3164/jcbn.20‑12933879970
     [Google Scholar]
  65. ZhangX. WongG.L.H. YipT.C.F. TseY.K. LiangL.Y. HuiV.W.K. LinH. LiG.L. LaiJ.C.T. ChanH.L.Y. WongV.W.S. Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease.Hepatology202276246948210.1002/hep.3229434939204
     [Google Scholar]
  66. ZengJ. Acin-PerezR. AssaliE.A. MartinA. BrownsteinA.J. PetcherskiA. Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in MASLDisease.Nat. Commun.2023141257310.1038/s41467‑023‑38165‑637142604
     [Google Scholar]
  67. ZhaoR. ZhuM. ZhouS. FengW. ChenH. Rapamycin-loaded mPEG-PLGA nanoparticles ameliorate hepatic steatosis and liver injury in MASL disease.Front Chem.20208
     [Google Scholar]
  68. WenL. LiM. LinX. LiY. SongH. ChenH. AgNPs aggravated hepatic steatosis, inflammation, oxidative stress, and epigenetic changes in mice with MASLD induced by HFD.Front. Bioeng. Biotechnol.202210
     [Google Scholar]
  69. AbbasiE. VafaeiS.A. NaseriN. DariniA. AzandaryaniM.T. AraF.K. Protective effects of cerium oxide nanoparticles in MASLDisease (MASLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver.Metabolism Open20211210015110.1016/j.metop.2021.10015134870139
     [Google Scholar]
  70. ZhaoW. BianY. WangQ. YinF. YinL. ZhangY. LiuJ. Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress.Acta Pharmacol. Sin.202243364565810.1038/s41401‑021‑00681‑w33990765
     [Google Scholar]
  71. LuJ. ZengY. ZhongH. GuoW. ZhangY. MaiW. Dual-stimuli-responsive gut microbiota-targeting nitidine chloride-CS/PT-NPs improved metabolic status in MASLDInt. J. Nanomed.2024192409242810.2147/IJN.S452194
     [Google Scholar]
  72. AbulikemuA. ZhaoX. XuH. LiY. MaR. YaoQ. WangJ. SunZ. LiY. GuoC. Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress.Redox Biol.20235910256910.1016/j.redox.2022.10256936512914
     [Google Scholar]
  73. AhmedE.S.A. MohamedH.E. FarragM.A. Luteolin loaded on zinc oxide nanoparticles ameliorates MASLDisease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway.Int. J. Immunopathol. Pharmacol.2022360394632022113743510.1177/0394632022113743536319192
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906321699241004070130
Loading
Decoding MASLD and the Link between Metabolic Dysfunction and Steatotic Liver Disease: An Overview
Int J Gastroenterol Hepatol Dis 3, e26662906321699 (2024); https://doi.org/10.2174/0126662906321699241004070130
/content/journals/ijghd/10.2174/0126662906321699241004070130
/content/journals/ijghd/10.2174/0126662906321699241004070130
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cerebrovascular dysfunction; Cognitive dysfunction; gut dysbiosis; metabolic dysfunction; nano formulations; steatotic liver disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test